CN3743070
Active
Amendment A1
National Supply arrangement for imported immunoglobulin products
The National Blood Authority has a limited-tender contract with CSL BEHRING (AUSTRALIA) PTY LTD valued at AU$1,874,602,218 for the national supply arrangement for imported immunoglobulin products. The contract runs from December 2020 to December 2027 and has one amendment. The limited tender was exempted under TR 10.3.d.iii due to an absence of competition for technical reasons.
$1.9B
Contract Value
Contract Details
- Contract ID
- CN3743070
- Status
- active
- Financial Year
- FY26
- Category
- Drugs and Pharmaceutical(UNSPSC: 51000000)
Key Dates
- Publish Date
- 9 June 2026
- Signed Date
- 19 Jan 2021
- Start Date
- 31 Dec 2020
- End Date
- 30 Dec 2027
- Duration
- 7 years, 1 month
Procurement Information
- Procurement Method
- Limited tender
- Exemption Code
- TR
- Exemption Reason
- 10.3.d.iii. Supply by particular business: due to an absence of competition for technical reasons.
Contract History
This contract has been amended 1 time. Currently showing amendment A1.
Original Contract
Published 19 Jan 2021 · 31 Dec 2020 to 30 Dec 2027
$806.8M
Amendment A1
Current
Published 9 June 2026 · 31 Dec 2020 to 30 Dec 2027
$1.9B
+$1.1B
Supplier
CSL BEHRING (AUSTRALIA) PTY LTD
- ABN
- 48 160 734 761
- Entity Type
- Australian Private Company
- Location
- VIC
Agency
More from CSL BEHRING (AUSTRALIA) PTY LTD
National Fractionation Agreement
$3.4BNational Blood Authority
Imported Plasma and Recombinant Products
$271.3MNational Blood Authority
Procurement of Imported Plasma and Recombinant Products (IPRP) - Idelvion
$73.6MNational Blood Authority
Imported Plasma and Recombinant Products (Factor XI Concentrate)
$8.3MNational Blood Authority
Pharmaceutical Products
$23KDepartment of Defence